Optimizing hormone therapy for future reproductive performance in women with premature ovarian failure

Gynecological Endocrinology

Volumn 27, Issue 1, 2011, Pages 1-7

  Gelbaya, Tarek ^a   Vitthala, Srisailesh ^b   Nardo, Luciano ^c   Seif, Morad ^c  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

assisted reproduction; endometrium; hormone therapy; Premature ovarian failure; uterus

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; PROGESTERONE;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; ENDOMETRIUM; ESTROGEN THERAPY; HORMONAL THERAPY; HUMAN; IRRADIATION; LOW DRUG DOSE; PREMATURE OVARIAN FAILURE; PRIMARY AMENORRHEA; PRIORITY JOURNAL; REPRODUCTIVE SUCCESS; REVIEW; SECONDARY AMENORRHEA; TREATMENT RESPONSE; TURNER SYNDROME; UTERUS GROWTH; UTERUS WEIGHT;

ADOLESCENT; AMENORRHEA; BODY HEIGHT; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OOCYTE DONATION; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; PROGESTERONE; PUBERTY; REPRODUCTION; REPRODUCTIVE TECHNIQUES, ASSISTED; TREATMENT OUTCOME;

EID: 78650138390     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.501875     Document Type: Review

References (72)

1. Coulam CB, Adamson SC, Anegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986;67:604-606. (Pubitemid 16116286)
2. Falsetti L, Scalchi S, Villani MT, Bugari G. Premature ovarian failure. Gynecol Endocrinol 1999;13:189-195. (Pubitemid 29313218)
3. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotrophic amenorrhea. Fertil Steril 1990;53: 804-810. (Pubitemid 20180467)
4. Conway GS, Kaltsas G, Patel A, Davies MC, Jacobs HS. Characterization of idiopathic premature ovarian failure. Fertil Steril 1996;65:337-341. (Pubitemid 26043830)
5. Tibiletti MG, Testa G, Vegetti W, Alagna F, Crosignani PG. The idiopathic forms of premature menopause and early menopause show the same genetic pattern. Hum Reprod 1999;14:2731-2734. (Pubitemid 29520682)
6. Chakravati S, Collins WP, Forecast JD, Newton JR, Orarn DH, Studd JW. Hormone profile after the menopause. Br Med J 1976;2:784-786.
7. Alzubaidi NH, Chapin HL, Vanderhoof VH, Calis KA, Nelson LM. Meting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol 2002;99:720-725. (Pubitemid 34442446)
8. Nelson LM, Anasti JN, Kimzey LM, Defensor RA, Lipetz KJ, White BJ, Shawker TH, Merino MJ. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab 1994;79:1470-75. (Pubitemid 24369868)
9. Jequier AM, Davis SR. The premature menopause: An example of a difficult diagnostic problem. In Programs and Abstracts of the 1st Australasian Menopause Society Congress, Perth, Australia; 1997.
10. Kreiner D, Droesch K, Navot D, Scott R, Rosenwaks Z. Spontaneous and pharmacologically induced remissions in patients with premature ovarian failure. Obstet Gynecol 1988;73:926-928.
11. van-Kasteren YM, Schoemaker J. Premature ovarian failure: A systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999;5:483-492. (Pubitemid 29512134)
12. Haber HP, Ranke MB. Pelvic ultrasonography in Turner's syndrome: Standards for uterine and ovarian volume. J Ultrasound Med 1999;18:271-276. (Pubitemid 29162548)
13. McDonnell CM, Coleman L, Zacharin RM. A 3-year prospective study to assess uterine growth in girls with Turner's syndrome by pelvic ultrasound. Clin Endocrinol 2003;58:446-450. (Pubitemid 36390616)
14. Kiess W, Conway G, Ritzen M, Rosenfield R, Bernasconi S, Juul A, van Pareren Y, de Muinck Keizer-Schrama SM, Bourguignon JP. Induction of puberty in the hypogonadal girlpractices and attitudes of pediatric endocrinologists in Europe. Horm Res 2002;57:66-71. (Pubitemid 34518763)
15. Hindmarsh PC. How to you initiate oestrogen therapy in a girl who has not undergone puberty? Clini Endocrinol 2009;71: 7-10.
16. Chernausek SD, Attie KM, Cara JF, Rosenfeld RG, Frane J. Growth hormone therapy of Turners syndrome: The impact of age of estrogen replacement on final height. J Clin Endocrinol Metab 2000;85:2439-2445. (Pubitemid 32269198)
17. Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, Hovatta O, Hultcrantz M, Landin-Wilhelmsen K, Lin A, Lippe B, et al. Recommendations for diagnosis and management of Turners syndrome. J Clin Endocrinol Metab 2001;86:3061-3069. (Pubitemid 32673466)
18. Bannink EM, van Sassen C, van Buuren S, de Jong FH, Lequin M, Mulder PG, de Muinck Keizer-Schrama SM. Puberty induction in Turner syndrome: Results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels. Clin Endocrinol 2009;70:265-273.
19. van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwé CW, et al. Final height in girls with turner syndrome after term growth hormone treatment in three dosages and low dose oestrogens. J Clin Endocrinol Metab 2003;88:1119-1125. (Pubitemid 36337765)
20. Reiter EO, Blethen SL, Baptista J, Price L. Early initiation of growth hormone treatment allows age appropriate estrogen use in Turners syndrome. J Clin Endocrinol Metab 2001;86: 1936-1941. (Pubitemid 32472901)
21. Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T Jr, Root AW. Salutary effects of combining early very low dose systemic oestradiol with growth hormone therapy in girls with Turners syndrome. J Clin Endocrinol Metab 2005;90: 6424-6430. (Pubitemid 41759295)
22. Zhang L, Rees MC, Bicknelle R. The isolation and long-term culture of normal human endometrial epithelium and stroma. Expression of mRNAs for angiogenic polypeptides basally and on oestrogen and progesterone challenges. J Cell Sci 1995; 108:323-331.
23. Abdalla HI, Brooks AA, Johnson MR, Kirkland A, Thomas A, Studd JWW. Endometrial thickness: A predictor of implantation in ovum recipients. Hum Reprod 1994;9:363-365. (Pubitemid 24076764)
24. Lippe B. Turner's syndrome. Endocrinol Metab Clin North Am 1991;20:121-152.
25. Khastgir G, Abdalla H, Thomas A, Korea L, Latarche L, Studd J. Oocyte donation in Turners syndrome: An analysis of factors affecting the outcome. Hum Reprod 1997;12: 279-285. (Pubitemid 27129387)
26. Yaron Y, Ochshorn Y, Amit A, Yovel I, Kogosowski A, Lessing JB. Patients with Turners syndrome may have an inherent endometrial abnormality affecting receptivity in oocyte donation. Fertil Steril 1996;65:1249-1252. (Pubitemid 26158651)
27. Li TC, Dockery P, Ramsewak SS, Klentzeris L, Lenton EA, Cooke ID. The variation of endometrial response to a standard hormone replacement therapy in women with premature ovarian failure. An ultasonographic and histological study. BJOG 1991;98:656-661.
28. Doerr HG, Bettendorf M, Hauffa BP, Mehls O, Partsch CJ, Said E, Sander S, Schwarz HP, Stahnke N, Steinkamp H, et al. Uterine size in women with Turner syndrome after induction of puberty with estrogens and long-term growth hormone therapy: Results of the German IGLU Follow-up Study 2001. Hum Reprod 2005;20:1418-1421. (Pubitemid 40790273)
29. Snajderova M, Mardesic T, Lebl J, Gerzova, Teslik L, Zapletalova. The uterine length in women with Turners Syndrome reflects the post menarcheal daily estrogen dose. Horm Res 2003;60:198-204. (Pubitemid 37256067)
30. Paterson WF, Hollman AS, Donaldson DC. Poor uterine development in Turner syndrome with oral oestrogen therapy. Clin Endocrinol 2002;56:359-365. (Pubitemid 34310014)
31. Bakalov VK, Shawker T, Ceniceros I, Bondy CA. Uterine development in Turner Syndrome. J Pediatr 2007;151: 528-531.
32. Piippo S, Lenko H, Kainulainen P, Sipilá I. Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. J Clin Endocrinol Metab 2004;89: 3241-3247. (Pubitemid 38951888)
33. Nabhan ZM, Dimeglio LA, Qi R, Perkins SM, Eugster EA. Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: A pilot comparative study. J Clin Endocrinol Metab 2009;94:2009-2014.
34. Bath LE, Critchley HOD, Chambers SE, Anderson RA, Kelnar CJH, Wallace WHB. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: Response to sex steroid replacement. BJOG 1999;106: 1265-1272.
35. Larsen EC, Schmiegelow K. Radiotherapy at a young reduces uterine volume of childhood cancer survivors. Acta Obstet Gynecol Scand 2004;83:96-102. (Pubitemid 38121736)
36. Critchley HOD, Wallace WHB, Shalet SM, Mamtora H, Higginson J, Anderson DC. Abdominal irradiation in childhood; the potential for pregnancy. BJOG 1992;99: 392-394.
37. Smith RA, Hawkins MM. Pregnancies after childhood cancer. Br J Obstet Gynecol 1989;96:378-390.
38. Merz E, Miric-Tesanic D, Bahlmann F, Wellek S. Sonographic size of uterus and ovaries in pre and postmenopausal women. Ultrasound Obstet Gynecol 1996;7:38-42. (Pubitemid 126720435)
39. Cagnacci A, Arangio S, Draetta FP, Angiolucci M, Volpe A, Melis GB. Transdermal administration of oestradiol and norethisterone: Effect on the uterus and uterine arteries. Menopause 2000;7:117-122. (Pubitemid 30151399)
40. Li TC, Cooke ID, Warren MA, Goolamallee, Graham RA, Aplin JD. Endometrial response in artificial cycles: A prospective study comparing four different oestrogen dosages. BJOG 1992;99:751-756.
41. Critchley HOD, Buckley HC, Anderson DC. Experience with a physiological steroid replacement regimen for the establishment of a receptive endometrium in women with premature ovarian failure. BJOG 1990;97:804-810. (Pubitemid 20283317)
42. Press F, Shapiro HM, Cowell CA, Oliver GD. Outcome of ovum donation in Turners syndrome patients. Fertil Steril 1995;64:995-998.
43. Fatemi HM, Bourgain C, Donoso P, Blockeel C, Papanikolaou EG, Popovic-Todorovic B, Devroey P. Effect of oral administration of dydrogestrone versus vaginal administration of natural micronized progesterone on the secretory transformation of endometrium and luteal endocrine profile in patients with premature ovarian failure: A proof of concept. Hum Reprod 2007;22:1260-1263. (Pubitemid 47062793)
44. Dallenbach-Hellweg G. The endometrium of infertility. A review. Pathol Res Pract 1984;178:527-538.
45. Jones GS. Luteal phase defect: A review of pathophysiology. Curr Opin Obstet Gynecol 1991;141:1123-1129.
46. Nardo LG, Sallam HN. Progesterone supplementation to prevent recurrent miscarriage and to reduce implantation failure in assisted reproductive cycles. Reprod Biomed Online 2006;13:47-57. (Pubitemid 44054845)
47. Guttmann H, Weiner Z, Nikolski E, Ish-Shalom S, Itskovitz- Eldor J, Aviram M, Reisner S, Hochberg Z. Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. Clin Endocrinol 2001;54:159-164. (Pubitemid 32193516)
48. Letur-Konirsch H, Delanian S. Successful pregnancies after combined pentoxifylline-tocopherol treatment in women with premature ovarian failure who are resistant to hormone replacement therapy. Fertil Steril 2002;77:1219-1226.
49. Novat D, Laufer N, Kopolovic J, et al. Artificially induced endometrial cycles and establishment of pregnancies in the absence of ovaries. N Engl J Med 1986;314:806-811. (Pubitemid 16138679)
50. Drobac S, Rubin K, Ragol AD, Rosenfield RL. A workshop on puberty hormone replacement options in United States. J Pediatr Endocrinol Metab 2006;19:55-64. (Pubitemid 43257421)
51. Leung KC, Johansson G, Leong GM,Ho KK. Estrogen regulation of growth hormone action. Endocr Rev 2004;25:693-721. (Pubitemid 39366048)
52. Aarskog D. Maternal progestins as a possible cause of hypospadias. N Engl J Med 1979;300:75-78. (Pubitemid 9104313)
53. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004;10:251-266.
54. Maruta A, Matsuzaki M, Miyashita H, Kodama F, Kato H, Taguchi J, Tomita N, Sakai R, Fujisawa S, Okubo T, et al. Successful pregnancy after allogeneic bone marrow transplantation following conditioning with total body irradiation. Bone Marrow Transplant 1995;15:637-638.
55. Green JM, Kafetsios K, Statham HE, Snowdon CM. Factor structure, validity and reliability of the Cambridge Worry Scale in a pregnant population. J Health Psychol 2003;8: 753-764. (Pubitemid 37377103)
56. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009;360:606-614.
57. Taylor AE. Systemic adversities of ovarian failure. J Soc Gynecol Investig 2001;8:S7-S9.
58. Vita JA, Keany JF Jr. Hormone replacement therapy and endothelial function. The exception that proves the rule? Arterioscler Thromb Vasc Biol 2001;21:1867-1869.
59. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714-718. (Pubitemid 26085645)
60. De Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002;155:339-345. (Pubitemid 34132052)
61. Jacobsen BK, Heuch I, Kvåle G. Age at natural menopause and all-cause mortality: A 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol 2003;157:923-929. (Pubitemid 36555052)
62. van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: Increased fracture risk at older age. Osteoporos Int 2003;14:525-530. (Pubitemid 36919215)
63. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77. (Pubitemid 46556472)
64. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57. (Pubitemid 34705518)
65. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425-2434. (Pubitemid 43948050)
66. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 2003;289:2673-2684. (Pubitemid 37430138)
67. Peverill RE. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 2003;17:149-164.
68. Scarabin PY, Oger E, Plu-Bureau G. Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432. (Pubitemid 36999704)
69. Beral V, Bull D, Reves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-1551.
70. Shah NR, Borenstein J, Dubois RW. Postmenopausal hormone therapy and breast cancer: A systematic review and meta-analysis. Menopause 2005;12:668-678. (Pubitemid 41669118)
71. Beral V, Million women Study collaborators, Bull D, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369: 1703-1710. (Pubitemid 46755369)
72. MHRA [internet]. Hormone replacement therapy: Update advice. Drug safety update. 2007. Electronic citation. http://www.mhra.gov.uk/Publications/ Safetyguidance/DrugSafety Update/CON2032234. Last accesses 18 January 2010.